Zhao Huang, Zhuangzhuang Cong, Jing Luo, Bingmei Qiu, Kang Wang, Chuan Gao, Yang Xu, Nan Yang, Zhiqiang Zou, Liwen Hu, Yi Shen
{"title":"Association between cancer-associated fibroblasts and prognosis of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a bioinformatics analysis based on single-cell RNA sequencing.","authors":"Zhao Huang, Zhuangzhuang Cong, Jing Luo, Bingmei Qiu, Kang Wang, Chuan Gao, Yang Xu, Nan Yang, Zhiqiang Zou, Liwen Hu, Yi Shen","doi":"10.1186/s12935-025-03709-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is a prevalent and aggressive subtype of esophageal cancer, posing a significant mortality and economic burden, especially in East and Southeast Asia. Current therapeutic strategies have limitations in improving patient survival, particularly regarding disease progression and resistance. This study aimed to investigate the impact of neoadjuvant chemoradiotherapy (NCRT) on the ESCC microenvironment.</p><p><strong>Methods: </strong>We utilized single-cell RNA sequencing to systematically characterize the tumor and cancer-associated fibroblasts (CAFs) subtypes. Marker genes of myofibroblastic CAFs (myCAFs) were employed to establish a prognostic model and verify its application in other datasets. Other experiments were conducted on clinical samples to explore potential ESCC risk-related genes.</p><p><strong>Results: </strong>Our bioinformatics and statistical analyses revealed an increased proportion of fibroblasts and epithelial cells in NCRT and identified the Ep_c1 subtype associated with a better prognosis. Further results indicated a complex communication network between Ep_c1 and myCAFs. The top 30 marker genes of myCAFs were used to construct a prognostic signature with a significant response to immunotherapy. Finally, experiments identified Complement C1s subcomponent (C1S), Decorin (DCN), and Neuroblastoma suppression of tumorigenicity 1 (NBL1) as potential ESCC risk-related genes.</p><p><strong>Conclusion: </strong>Our findings highlight the dynamic alterations in the post-NCRT ESCC microenvironment and provide a foundation for the development of personalized treatment and immunotherapeutic approaches. Future studies are warranted to further validate these findings and explore their clinical implications.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"74"},"PeriodicalIF":5.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03709-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:食管鳞状细胞癌(ESCC)是食管癌中普遍存在的一种侵袭性亚型,对死亡率和经济造成了巨大负担,尤其是在东亚和东南亚地区。目前的治疗策略在提高患者生存率方面存在局限性,尤其是在疾病进展和耐药性方面。本研究旨在探讨新辅助化放疗(NCRT)对ESCC微环境的影响:方法:我们利用单细胞 RNA 测序系统地描述了肿瘤和癌症相关成纤维细胞(CAFs)亚型的特征。我们利用肌成纤维细胞(myCAFs)的标记基因建立了一个预后模型,并在其他数据集中验证了该模型的应用。我们还对临床样本进行了其他实验,以探索潜在的 ESCC 风险相关基因:结果:我们的生物信息学和统计学分析表明,NCRT中成纤维细胞和上皮细胞的比例增加,并确定了Ep_c1亚型与较好的预后相关。进一步的研究结果表明,Ep_c1和myCAF之间存在复杂的通讯网络。myCAFs的前30个标记基因被用于构建对免疫疗法有显著反应的预后特征。最后,实验发现补体C1s亚组分(C1S)、Decorin(DCN)和Neuroblastoma suppression of tumorigenicity 1(NBL1)是潜在的ESCC风险相关基因:我们的研究结果突显了NCRT后ESCC微环境的动态变化,为开发个性化治疗和免疫治疗方法奠定了基础。未来的研究需要进一步验证这些发现并探索其临床意义。
Association between cancer-associated fibroblasts and prognosis of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a bioinformatics analysis based on single-cell RNA sequencing.
Background: Esophageal squamous cell carcinoma (ESCC) is a prevalent and aggressive subtype of esophageal cancer, posing a significant mortality and economic burden, especially in East and Southeast Asia. Current therapeutic strategies have limitations in improving patient survival, particularly regarding disease progression and resistance. This study aimed to investigate the impact of neoadjuvant chemoradiotherapy (NCRT) on the ESCC microenvironment.
Methods: We utilized single-cell RNA sequencing to systematically characterize the tumor and cancer-associated fibroblasts (CAFs) subtypes. Marker genes of myofibroblastic CAFs (myCAFs) were employed to establish a prognostic model and verify its application in other datasets. Other experiments were conducted on clinical samples to explore potential ESCC risk-related genes.
Results: Our bioinformatics and statistical analyses revealed an increased proportion of fibroblasts and epithelial cells in NCRT and identified the Ep_c1 subtype associated with a better prognosis. Further results indicated a complex communication network between Ep_c1 and myCAFs. The top 30 marker genes of myCAFs were used to construct a prognostic signature with a significant response to immunotherapy. Finally, experiments identified Complement C1s subcomponent (C1S), Decorin (DCN), and Neuroblastoma suppression of tumorigenicity 1 (NBL1) as potential ESCC risk-related genes.
Conclusion: Our findings highlight the dynamic alterations in the post-NCRT ESCC microenvironment and provide a foundation for the development of personalized treatment and immunotherapeutic approaches. Future studies are warranted to further validate these findings and explore their clinical implications.
期刊介绍:
Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques.
The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors.
Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.